We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $140.45, moving +1.02% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.18%. Elsewhere, the Dow saw an upswing of 0.66%, while the tech-heavy Nasdaq appreciated by 1.96%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 4.26% in the past month. In that same time, the Medical sector lost 1.56%, while the S&P 500 gained 3.93%.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on May 7, 2026. It is anticipated that the company will report an EPS of $1.87, marking a 3.31% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $6.88 billion, up 3.13% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.65 per share and a revenue of $30.15 billion, indicating changes of +6.13% and +2.39%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% lower. At present, Gilead Sciences boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Gilead Sciences is at present trading with a Forward P/E ratio of 16.07. This signifies a discount in comparison to the average Forward P/E of 19.6 for its industry.
Meanwhile, GILD's PEG ratio is currently 1.85. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.6 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 141, this industry ranks in the bottom 43% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $140.45, moving +1.02% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.18%. Elsewhere, the Dow saw an upswing of 0.66%, while the tech-heavy Nasdaq appreciated by 1.96%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 4.26% in the past month. In that same time, the Medical sector lost 1.56%, while the S&P 500 gained 3.93%.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on May 7, 2026. It is anticipated that the company will report an EPS of $1.87, marking a 3.31% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $6.88 billion, up 3.13% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.65 per share and a revenue of $30.15 billion, indicating changes of +6.13% and +2.39%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% lower. At present, Gilead Sciences boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Gilead Sciences is at present trading with a Forward P/E ratio of 16.07. This signifies a discount in comparison to the average Forward P/E of 19.6 for its industry.
Meanwhile, GILD's PEG ratio is currently 1.85. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.6 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 141, this industry ranks in the bottom 43% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.